Bevicra 100 mg Injection
  1. Home
  2. Pharma Products
  3. Glenmark Pharmaceuticals Ltd
  4. Bevicra 100 mg Injection

Bevicra 100 mg Injection

Bevicra 100 mg Injection contains bevacizumab 100 mg and is an anticancer medicine used in the treatment of several advanced cancers. It is supplied as a 100 mg/4 mL solution and is administered by intravenous infusion under the supervision of a qualified healthcare professional. Bevacizumab works by blocking vascular endothelial growth factor (VEGF), which helps limit the formation of blood vessels that support tumor growth.

BUY NOW

Category

Bevicra is a monoclonal antibody used with other anticancer medicines in appropriate treatment regimens for conditions including colorectal cancer, non-small cell lung cancer, kidney cancer, cervical cancer, and ovarian-related cancers. By inhibiting VEGF signaling, bevacizumab interferes with tumor angiogenesis and reduces the blood supply available to growing tumors. The dose and treatment schedule depend on the cancer type and the prescribed oncology protocol. Treatment requires medical monitoring because bevacizumab may be associated with hypertension, bleeding, proteinuria, impaired wound healing, and infusion-related reactions.

Technical Specification

Specification Details
Active Ingredient Bevacizumab
Strength 100 mg
Presentation 100 mg/4 mL
Concentration 25 mg/mL
Dosage Form Solution for Infusion
Manufacturer Glenmark Pharmaceuticals Ltd

Product Also Known As

Bevicra 100mg Injection, Bevicra 100mg/4ml Injection, Bevacizumab 100mg Injection, Bevacizumab 100mg/4ml Infusion, Bevacizumab Injection 100mg, Bevacizumab 25mg/ml Infusion